Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The epidemiology of osteoporotic fractures.in: Primer on the metabolic bone diseases and disorders of mineral metabolism. 2018: 398-404
- Polypharmacy in the elderly: a literature review.J Am Acad Nurse Pract. 2005; 17: 123-132
- Defining polypharmacy in the elderly: a systematic review protocol.BMJ Open. 2016; 6: e010989
- Potential pitfalls of disease-specific guidelines for patients with multiple conditions.N Engl J Med. 2004; 351: 2870-2874
- Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study.Medicine (Baltimore). 2010; 89: 295-299
- The association between polypharmacy and hip fracture in osteoporotic women: a nested case–control study in South Korea.Clin Drug Invest. 2019; 39: 63-71
- Association of polypharmacy with fall-related fractures in older Taiwanese people: age- and gender-specific analyses.BMJ Open. 2014; 4: e004428
- A systematic review of factors affecting medication adherence among patients with osteoporosis.Osteoporos Int. 2018; 29: 2623-2637
- Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.Am J Med. 2009; 122: S3-S13
- Loss of treatment benefit due to low compliance with bisphosphonate therapy.Osteoporos Int. 2008; 19: 511-517
- Compliance with osteoporosis drug therapy and risk of fracture.Osteoporos Int. 2007; 18: 271-277
- The impact of teriparatide adherence and persistence on fracture outcomes.Osteoporos Int. 2012; 23: 1103-1113
- Compliance with osteoporosis medications.Arch Intern Med. 2005; 165: 2414-2419
- Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.J Am Geriatr Soc. 2014; 62: 2261-2272
- Association between polypharmacy and falls in older adults: a longitudinal study from England.BMJ Open. 2017; 7: e016358
- American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary.Endocr Pract. 2020; 26: 564-570
- Osteoporosis.Lancet. 2019; 393: 364-376
- Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.JAMA. 1998; 280: 2077-2082
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.Lancet. 1996; 348: 1535-1541
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.JAMA. 1999; 282: 1344-1352
- Effect of risedronate on the risk of hip fracture in elderly women.N Engl J Med. 2001; 344: 333-340
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med. 2007; 356: 1809-1822
- Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med. 2007; 357: 1799-1809
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009; 361: 756-765
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.Lancet Diabetes Endocrinol. 2017; 5: 513-523
- Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the american college of physicians.Ann Intern Med. 2017; 166: 818-839
- Pharmacological management of osteoporosis in postmenopausal women: an endocrine society∗ clinical practice guideline.J Clin Endocrinol Metab. 2019; 104: 1595-1622
- Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.J Bone Miner Res. 2004; 19: 1241-1249
- Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.J Clin Endocrinol Metab. 2019; 104: 1623-1630
- Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension.J Bone Miner Res. 2018; 33: 190-198
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med. 2001; 344: 1434-1441
- Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.JAMA. 2016; 316: 722-733
- Romosozumab treatment in postmenopausal women with osteoporosis.N Engl J Med. 2016; 375: 1532-1543
- Romosozumab or alendronate for fracture prevention in women with osteoporosis.N Engl J Med. 2017; 377: 1417-1427
- Romosozumab in postmenopausal women with low bone mineral density.N Engl J Med. 2014; 370: 412-420
- Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.Osteoporos Int. 2020; 31: 1019-1021
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.Lancet. 2018; 391: 230-240
- The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update.Bone. 2020; 137: 115457
- The impact of diabetic neuropathy on activities of daily living, postural balance and risk of falls - a systematic review.J Diabetes Sci Technol. 2021; 16: 289-294
- Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies.Osteoporos Int. 2021; 32: 1693-1704
- Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis.Bone. 2019; 120: 1-8
- Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis.Bone. 2014; 67: 246-256
- Imminent risk of fracture after fracture.Osteoporos Int. 2017; 28: 775-780
- Nonadherence and osteoporosis treatment preferences of older women: a qualitative study.J Women's Health (2002). 2003; 12: 1037-1045
- Fracture prevention with zoledronate in older women with osteopenia.N Engl J Med. 2018; 379: 2407-2416
- Five years of anti-resorptive activity after a single dose of zoledronate — results from a randomized double-blind placebo-controlled trial.Bone. 2012; 50: 1389-1393
- Ten years of very infrequent zoledronate therapy in older women: an open-label extension of a randomized trial.J Clin Endocrinol Metab. 2020; 105: dgaa062
Article info
Publication history
Published online: September 13, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
